REXO2 Activators
REXO2 Activators, in the context of the chemicals listed, represent a range of compounds that indirectly enhance the expression or activity of REXO2 through their influence on RNA synthesis, processing, or turnover. These chemicals act primarily by inducing cellular stress or by disrupting normal RNA and protein synthesis pathways, which can result in the accumulation of misfolded RNAs and aberrant RNA species. Such an accumulation is likely to stimulate REXO2 activity as the enzyme responds to maintain RNA integrity and cellular homeostasis.
Each of these compounds can cause an indirect upregulation of REXO2 by creating a cellular environment that requires enhanced RNA surveillance and degradation. For example, Actinomycin D and DRB by inhibiting transcription, not only reduce the overall RNA synthesis but also may lead to an accumulation of abnormal RNA transcripts that REXO2 is responsible for degrading. Similarly, proteasome inhibitors like MG132 can induce a state where defective ribosomal products accumulate, necessitating increased REXO2 activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor that could lead to increased levels of misfolded proteins, indirectly affecting RNA metabolism pathways and possibly enhancing REXO2 function for RNA quality control. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $166.00 $322.00 | 436 | |
Inhibits protein synthesis and could increase the production of defective ribosomal products (DRiPs), indirectly upregulating REXO2 activity as part of the cellular response to misfolded RNAs. | ||||||
Sodium (meta)arsenite | 7784-46-5 | sc-250986 sc-250986A | 100 g 1 kg | $108.00 $780.00 | 3 | |
Induces oxidative stress, potentially enhancing REXO2 activity to deal with the increased RNA damage. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Cyclin-dependent kinase inhibitor that can halt cell cycle progression and influence RNA polymerase II activity, possibly requiring enhanced REXO2 activity for RNA quality control. | ||||||
β-Lapachone | 4707-32-8 | sc-200875 sc-200875A | 5 mg 25 mg | $112.00 $459.00 | 8 | |
Induces DNA damage responses and can influence RNA metabolism pathways, possibly enhancing the role of REXO2 in RNA damage surveillance. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Topoisomerase inhibitor that can lead to DNA damage and interfere with RNA processing, potentially increasing the demand for REXO2 activity. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Topoisomerase II inhibitor that may indirectly upregulate REXO2 by increasing RNA misprocessing and aberrant RNA species that require degradation. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Thymidylate synthase inhibitor that affects DNA and RNA synthesis, potentially inducing REXO2 activity to counteract increased RNA instability and turnover. | ||||||